Literature DB >> 20827203

Mitochondrial pathology in immune and inflammatory myopathies.

Arun S Varadhachary1, Conrad C Weihl, Alan Pestronk.   

Abstract

PURPOSE OF REVIEW: Acquired immune and inflammatory myopathies (IIMs) are typically subdivided into dermatomyositis, polymyositis and inclusion body myositis. However, many types of IIMs do not fit well into this scheme. Several myopathologic and autoantibody features of IIMs, that are not considered in standard classifications, are useful for defining individual disorders. We will review one set of myopathologic features that occur in some IIMs, mitochondrial abnormalities, and consider its diagnostic, treatment-related and pathogenic implications. RECENT
FINDINGS: Myopathologic changes that indicate mitochondrial disorders are often widespread in regions of muscle fiber abnormality in dermatomyositis. They distinguish dermatomyositis with vascular pathology from other inflammatory myopathies with skin changes that have prominent perimysial connective tissue lesions, but no mitochondrial, abnormalities. Mitochondrial abnormalities in scattered muscle fibers occur in sporadic inclusion body myositis and clinically similar disorders. Mitochondrial abnormalities in scattered nonnecrotic muscle fibers in IIM biopsies predict a poor response to immunosuppression.
SUMMARY: Muscle biopsy, including evaluation of mitochondrial stains, is important for the correct diagnosis of inflammatory myopathies. By recognizing the full range of distinctive myopathologic changes in the diverse group of IIMs, the clinician can improve diagnostic accuracy and apply appropriate treatment.

Entities:  

Mesh:

Year:  2010        PMID: 20827203     DOI: 10.1097/BOR.0b013e32833f108a

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  8 in total

1.  Anti-aminoacyl-tRNA synthetase-related myositis and dermatomyositis: clues for differential diagnosis on muscle biopsy.

Authors:  Bruna Cerbelli; Annalinda Pisano; Serena Colafrancesco; Maria Gemma Pignataro; Marco Biffoni; Silvia Berni; Antonia De Luca; Valeria Riccieri; Roberta Priori; Guido Valesini; Giulia d'Amati; Carla Giordano
Journal:  Virchows Arch       Date:  2017-11-16       Impact factor: 4.064

2.  Chronic progressive external ophthalmoplegia with inflammatory myopathy.

Authors:  Ting Chen; Chuanqiang Pu; Qiang Shi; Qian Wang; Lu Cong; Jiexiao Liu; Hongyu Luo; Lingna Fei; Wei Tang; Shanshan Yu
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

Review 3.  Polymyositis with mitochondrial pathology or atypical form of sporadic inclusion body myositis: case series and review of the literature.

Authors:  George K Papadimas; Charalampos Kokkinis; Sophia Xirou; Margarita Chrysanthou; Evangelia Kararizou; Constantinos Papadopoulos
Journal:  Rheumatol Int       Date:  2019-05-04       Impact factor: 2.631

Review 4.  New insights into the benefits of exercise for muscle health in patients with idiopathic inflammatory myositis.

Authors:  Li Alemo Munters; Helene Alexanderson; Leslie J Crofford; Ingrid E Lundberg
Journal:  Curr Rheumatol Rep       Date:  2014-07       Impact factor: 4.592

5.  Metabolic myopathy presenting with polyarteritis nodosa: a case report.

Authors:  Sahana Vishwanath; Mishal Abdullah; Amro Elbalkhi; Julian L Ambrus
Journal:  J Med Case Rep       Date:  2011-06-30

6.  A Mutation in the Mitochondrial Aspartate/Glutamate Carrier Leads to a More Oxidizing Intramitochondrial Environment and an Inflammatory Myopathy in Dutch Shepherd Dogs.

Authors:  G Diane Shelton; Katie M Minor; Kefeng Li; Jane C Naviaux; Jon Monk; Lin Wang; Elizabeth Guzik; Ling T Guo; Vito Porcelli; Ruggiero Gorgoglione; Francesco M Lasorsa; Peter J Leegwater; Antonio M Persico; James R Mickelson; Luigi Palmieri; Robert K Naviaux
Journal:  J Neuromuscul Dis       Date:  2019

7.  Scleroderma-polymyositis overlap syndrome versus idiopathic polymyositis and systemic sclerosis: a descriptive study on clinical features and myopathology.

Authors:  Kavish J Bhansing; Martin Lammens; Hanneke K A Knaapen; Piet L C M van Riel; Baziel G M van Engelen; Madelon C Vonk
Journal:  Arthritis Res Ther       Date:  2014-05-13       Impact factor: 5.156

8.  3-n-Butylphthalide reduces the oxidative damage of muscles in an experimental autoimmune myositis animal model.

Authors:  Juan Chen; Jingyang Wang; Jiyan Zhang; Chuanqiang Pu
Journal:  Exp Ther Med       Date:  2017-07-11       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.